TGF-β-Neutralizing Antibody 1D11 Enhances Cytarabine-Induced Apoptosis in AML Cells in the Bone Marrow Microenvironment

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Tabe, Yoko ^a,b   Shi, Yue Xi ^a   Zeng, Zhihong ^a   Jin, Linhua ^b   Shikami, Masato ^c   Hatanaka, Yasuhito ^b   Miida, Takashi ^b   Hsu, Frank J ^d   Andreeff, Michael ^a   Konopleva, Marina ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c AICHI MEDICAL UNIVERSITY   (Japan)

^d GENZYME CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 D11 ANTIBODY; CHEMOKINE RECEPTOR CXCR4; CYTARABINE; PLERIXAFOR; RECOMBINANT TRANSFORMING GROWTH FACTOR BETA2; SMAD2 PROTEIN; STROMAL CELL DERIVED FACTOR 1; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CXCL12 PROTEIN, HUMAN; CXCR4 PROTEIN, HUMAN; CXCR4 PROTEIN, MOUSE; HETEROCYCLIC COMPOUND; NEUTRALIZING ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE MARROW; CANCER COMBINATION CHEMOTHERAPY; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL INTERACTION; CELL MIGRATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENE TARGETING; HUMAN; HUMAN CELL; LEUKEMIA CELL; MICROENVIRONMENT; MOUSE; NONHUMAN; ONCOGENE; PAI 1 GENE; PHARMACOLOGICAL BLOCKING; PROTEIN PHOSPHORYLATION; TREATMENT RESPONSE; ANIMAL; ANTAGONISTS AND INHIBITORS; CANCER TRANSPLANTATION; CELL MOTION; CELL SURVIVAL; COCULTURE; DRUG EFFECTS; IMMUNOLOGY; LEUKEMIA, MYELOID, ACUTE; METABOLISM; PHYSIOLOGY; SCID MOUSE; TUMOR CELL LINE; TUMOR MICROENVIRONMENT;

ARA;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTINEOPLASTIC AGENTS; APOPTOSIS; BONE MARROW; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; CHEMOKINE CXCL12; COCULTURE TECHNIQUES; CYTARABINE; FEMALE; HETEROCYCLIC COMPOUNDS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MICE, SCID; NEOPLASM TRANSPLANTATION; RECEPTORS, CXCR4; TRANSFORMING GROWTH FACTOR BETA; TUMOR MICROENVIRONMENT;

EID: 84879542661     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0062785     Document Type: Article

References (49)

1. Garrido SM, Appelbaum FR, Willman CL, Banker DE, (2001) Acute myeloid leukemia cells are protected from spontaneous and drug-induced apoptosis by direct contact with a human bone marrow stromal cell line (HS-5). Experimental Hematology 29: 448-457.
2. Taichman RS, (2005) Blood and bone: two tissues whose fates are intertwined to create the hematopoietic stem-cell niche. Blood 105: 2631-2639.
3. Balooch G, Balooch M, Nalla RK, Schilling S, Filvaroff EH, et al. (2005) TGF-beta regulates the mechanical properties and composition of bone matrix. Proc Natl Acad Sci U S A 102: 18813-18818.
4. Shin I, Bakin AV, Rodeck U, Brunet A, Arteaga CL, (2001) Transforming growth factor beta enhances epithelial cell survival via Akt-dependent regulation of FKHRL1. Mol Biol Cell 12: 3328-3339.
5. Jang CW, Chen CH, Chen CC, Chen JY, Su YH, (2002) TGF-beta induces apoptosis through Smad-mediated expression of DAP-kinase. Nature Cell Biol 4: 51-58.
6. Massague J, (2000) How cells read TGF-beta signals. Nat Rev Mol Cell Biol 1: 169-178.
7. Narayan S, Thangasamy T, Balusu R, (2005) Transforming growth factor-beta receptor signaling in cancer. Front Biosci 10: 1135-1145.
8. Massague J, Gomis RR, (2006) The logic of TGFbeta signaling. FEBS Lett 580: 2811-2820.
9. Fortunel NO, Hatzfeld A, Hatzfeld JA, (2000) Transforming growth factor-beta: pleiotropic role in the regulation of hematopoiesis. Blood 96: 2022-2036.
10. Ruscetti FW, Akel S, Bartelmez SH, (2005) Autocrine transforming growth factor-beta regulation of hematopoiesis: many outcomes that depend on the context. Oncogene 24: 5751-5763.
11. Xu Y, Tabe Y, Jin L, Watt J, McQueen T, et al. (2008) TGF-beta receptor kinase inhibitor LY2109761 reverses the anti-apoptotic effects of TGF-beta1 in myelo-monocytic leukaemic cells co-cultured with stromal cells. Br J Haematol 142: 192-201.
12. Chin BY, Petrache I, Choi AM, Choi ME, (1999) Transforming growth factor beta1 rescues serum deprivation-induced apoptosis via the mitogen-activated protein kinase (MAPK) pathway in macrophages. J Biol Chem 274: 11362-11368.
13. Hayashi T, Hideshima T, Nguyen AN, Munoz O, Podar K, et al. (2004) Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment. Clin Cancer Res 10: 7540-7546.
14. Leask A, Abraham DJ, (2004) TGF-beta signaling and the fibrotic response. FASEB J 18: 816-827.
15. Blobe GC, Schiemann WP, Lodish HF, (2000) Role of transforming growth factor beta in human disease. N Engl J Med 342: 1350-1358.
16. Kim CH, Broxmeyer HE, (1998) In vitro behaviour of hematopoietic progenitor cells under the influence of chemoattractants: stromal cell-derived factor-1, steel factor, and the bone marrow microenvironment. Blood 91: 100-110.
17. Buckley CD, Amft N, Bradfield PF, Pilling D, Ross E, et al. (2000) Persistent induction of the chemokine receptor CXCR4 by TGF-beta 1 on synovial T cells contributes to their accumulation within the rheumatoid synovium. J Immunol 165: 3423-3429.
18. Katoh M, Katoh M, (2010) Integrative genomic analyses of CXCR4: transcriptional regulation of CXCR4 based on TGFbeta, Nodal, Activin signaling and POU5F1, FOXA2, FOXC2, FOXH1, SOX17, and GFI1 transcription factors. Int J Oncol 36: 415-420.
19. Parmar K, Mauch P, Vergilio JA, Sackstein R, Down JD, (2007) Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxia. Proc Natl Acad Sci U S A 104: 5431-5436.
20. Mortensen BT, Jensen PO, Helledie N, Iversen PO, Ralfkiaer E, et al. (1998) Changing bone marrow micro-environment during development of acute myeloid leukaemia in rats. Br J Haematol 102: 458-464.
21. Benito J, Shi Y, Szymanska B, Carol H, Boehm I, et al. (2011) Pronounced Hypoxia in Models of Murine and Human Leukemia: High Efficacy of Hypoxia-Activated Prodrug PR-104. Plos One 6: e23108.
22. Saed GM, Collins KL, Diamond MP, (2002) Transforming growth factors beta1, beta2 and beta3 and their receptors are differentially expressed in human peritoneal fibroblasts in response to hypoxia. Am J Reprod Immunol 48: 387-393.
23. Zhang H, Akman HO, Smith EL, Zhao J, Murphy-Ullrich JE, et al. (2003) Cellular response to hypoxia involves signaling via Smad proteins. Blood 101: 2253-2260.
24. Piret JP, Mottet D, Raes M, Michiels C, (2002) Is HIF-1alpha a pro- or an anti-apoptotic protein? Biochem Pharmacol 64: 889-892.
25. Schioppa T, Uranchimeg B, Saccani A, Biswas SK, Doni A, et al. (2003) Regulation of the chemokine receptor CXCR4 by hypoxia. J Exp Med 198: 1391-1402.
26. Fiegl M, Samudio I, Clise-Dwyer K, Burks JK, Mnjoyan Z, et al. (2009) CXCR4 expression and biologic activity in acute myeloid leukemia are dependent on oxygen partial pressure. Blood 113: 1504-1512.
27. Dasch JR, Pace DR, Waegell W, Inenaga D, Ellingsworth L, (1989) Monoclonal antibodies recognizing transforming growth factor-beta. Bioactivity neutralization and transforming growth factor beta 2 affinity purification. J Immunol 142: 1536-1541.
28. Small D, Levenstein M, Kim E, Carow C, Amin S, et al. (1994) STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells. Proc Natl Acad Sci U S A 91: 459-463.
29. Gilliland DG, Griffin JD, (2002) The roles of FLT3 in hematopoiesis and leukemia. Blood 100: 1532-1542.
30. Nakao M, Yokota S, Iwai T, Kaneko H, Horiike S, et al. (1996) Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 10: 1911-1918.
31. Levis M, Allebach J, Tse KF, Zheng R, Badwin BR, et al. (2002) A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood 99: 3885-3891.
32. Palacios R, Steinmetz M, (1985) Il-3-dependent mouse clones that express B-220 surface antigen, contain Ig genes in germ-line configuration, and generate B lymphocytes in vivo. Cell 41: 727-734.
33. Tabe Y, Konopleva M, Munsell MF, Marini FC, Zompetta C, et al. (2004) PML-RARα is associated with leptin-receptor induction: the role of mesenchymal stem cell-derived adipocytes in APL cell survival. Blood 103: 1815-1822.
34. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, et al. (1999) Multilineage potential of adult human mesenchymal stem cells. Science 284: 143-147.
35. Tabe Y, Jin L, Tsutsumi-Ishii Y, Xu Y, McQueen T, et al. (2007) Activation of integrin-linked kinase is a critical prosurvival pathway induced in leukemic cells by bone marrow-derived stromal cells. Cancer Res 67: 684-694.
36. Konopleva M, Konoplev S, Hu W, Zaritskey AY, Afanasiev BV, et al. (2002) Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins. Leukemia 16: 1713-1724.
37. Dallas SL, Park-Snyder S, Miyazono K, Twardzik D, Mundy GR, et al. (1994) Characterization and autoregulation of latent transforming growth factor beta (TGF beta) complexes in osteoblast-like cell lines. Production of a latent complex lacking the latent TGF beta-binding protein. J Biol Chem 269: 6815-6821.
38. Fortunel NO, Hatzfeld A, Hatzfeld JA, (2000) Transforming growth factor-beta: pleiotropic role in the regulation of hematopoiesis. Blood 96: 2022-2036.
39. Burger JA, Peled A, (2009) CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers. Leukemia 23: 43-52.
40. Zeng Z, Shi YX, Samudio IJ, Wang RY, Ling X, et al. (2009) Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood 113: 6215-6224.
41. Soma T, Yu JM, Dunbar CE, (1996) Maintenance of murine long-term repopulating stem cells in ex vivo culture is affected by modulation of transforming growth factor-beta but not macrophage inflammatory protein-1 alpha activities. Blood 87: 4561-4567.
42. Blank U, Karlsson S, (2011) The role of Smad signaling in hematopoiesis and translational hematology. Leukemia 25: 1379-1388.
43. Frisch BJ, Ashton JM, Xing L, Becker MW, Jordan CT, et al. (2012) Functional inhibition of osteoblastic cells in an in vivo mouse model of myeloid leukemia. Blood 119: 540-550.
44. Balooch G, Balooch M, Nalla RK, Schilling S, Filvaroff EH, et al. (2005) TGF-beta regulates the mechanical properties and composition of bone matrix. Proc Natl Acad Sci U S A 102: 18813-18.
45. Ao M, Williams K, Bhowmick NA, Hayward SW, (2006) Transforming growth factor-β promotes invasion in tumorigenic but not in nontumorigenic human prostatic epithelial cells. Cancer Res 66: 8007-8016.
46. Ao M, Franco OE, Park D, Raman D, Williams K, et al. (2007) Cross-talk between paracrine-acting cytokine and chemokine pathways promotes malignancy in benign human prostatic epithelium. Cancer Res 67: 4244-4253.
47. Kojima Y, Acar A, Eaton EN, Mellody KT, Scheel C, et al. (2010) Autocrine TGF-beta and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts. Proc Natl Acad Sci U S A 107: 20009-200014.
48. Ruzek MC, Hawes M, Pratt B, McPherson J, Ledbetter S, et al. (2003) Minimal effects on immune parameters following chronic anti-TGF-beta monoclonal antibody administration to normal mice. Immunopharmacol Immunotoxicol 25: 235-237.
49. Morris JC, Shapiro GI, Tan AR, Lawrence DP, Olencki TE, et al. (2008) Phase I/II Study of GC1008: A human anti-transforming growth factor-beta (TGFb) monoclonal antibody (MAb) in patients with advanced malignant melanoma (MM) or renal cell carcinoma (RCC). J Clin Oncol 26: abstr 9028.